Figure 1
Comparison of survival curves of OGS (+) and negative AML patients. We would like to make following comments on this study. First, we should mention that the data was well analyzed particularly from a statistical point of view. We agree with the authors that extramedullary leukemia (EML) is more common in the M4 or M5 subtype of AML. In our series, EML in the form of orbito-ocular or orbital granulocytic leukemia (OGS) was also more common in M4 subtype of AML. 2, 3 OGS is a subgroup of granulocytic sarcoma (GS) that we have been interested in for many years. However, it seems to us that a very important finding, namely orbital localization of myeloblastoma or granulocytic sarcoma (GS) in 35 Dutch children is entirely overlooked. This localization of GS has generally been considered as an unusual or a rare finding in the Western world, in contrast to African and Asian countries. [2] [3] [4] Surprisingly, despite the presence of this important finding, no comment has been made on orbital localization, rather other EML involvements such as gingiva, CNS and skin, have been stressed. EML is a general term and the orbital form represents a subgroup, usually named either 'orbital chloroma' or OGS. 2, 3 Furthermore, there was no information about the race or ethnic origin and the socio-economic status (SES) of the patients, although ethnic diversity in The Netherlands is well known. Interestingly, in recent series of childhood GS reported from South Africa, GS occurred in 60% exclusively in black male children, mostly in orbital form, associated with t(8:21), indicating possible role of race and/or sex. 5 In our series, the OGS subgroup was from low SES within Turkey. 3, 6 This was reflected by their T cell immunity (diminished delayed hypersensivity reaction and low T cell counts, etc) prior to their treatment. 6 The presence of OGS in 33 children associated with AML had unfavorably affected the prognosis in our series. In fact, none survived in this group and the mean survival time of 8.7 months was significantly shorter (P Ͻ 0.01) compared with 28.6 months in the AML group without OGS, despite the fact that they had received similar chemotherapy regimens (Figure 1 dren should receive intensive chemotherapy, local radiotherapy to orbit and bone marrow transplantation (BMT), in order to have better survival. 3 Although intensive chemo-radiotherapy regimens have been used since 1990, and have improved the mean survival time in the OGS group of AML, overall prognosis has not changed significantly (unpublished data).
Leukemia
Our recent finding of expression of adhesion molecules CD56 and CD44, in the blast cells of some of our patients with OGS in addition to MDR (P-glycoprotein) expression might explain the different prognosis in Turkish children with OGS and AML. 7 The presence of t(8;21)(q22;22) did not have a favorable effect on the prognosis of OGS and AML observed in our series. The prognosis of GS is still unclear, although the general impression obtained from the literature is that this group behaves poorly compared to AML patients. 3, 5 Nearly half of the 31 children with AML and GS in Pui et al 8 series from St Jude hospital, died and 23% reoccurred.
Therefore, we are of the opinion that OGS represents a biologically heterogeneous subgroup of AML. Further molecular, cytogenetic and immunologic studies are needed to understand the variable features of myeloblastoma or GS.
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